NCT00533351View on ClinicalTrials.gov

Safety and Efficacy of AGN201781 in Neuropathic Pain

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Neuralgia
Interventions
DRUG

AGN201781

AGN201781 50 mg capsules three-times daily for 2 weeks

DRUG

placebo

placebo 50 mg capsules three-times daily for 2 weeks

Trial Locations (2)

Unknown

St Leonards

Kiel

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT00533351 - Safety and Efficacy of AGN201781 in Neuropathic Pain | Biotech Hunter | Biotech Hunter